Back to top
more

Maravai LifeSciences (MRVI)

(Delayed Data from NSDQ)

$2.34 USD

2.34
1,391,423

+0.07 (3.08%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $2.34 0.00 (0.00%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -14.29% and 5.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of -50% and 3.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

MariMed Inc. (MRMD) delivered earnings and revenue surprises of 0% and 0.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 4.03% and 2.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

DENTSPLY SIRONA to Post Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.

Zacks Equity Research

Will BAX's Q4 Earnings Reflect Its Efforts to Counter Headwinds?

by Zacks Equity Research

Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, pharmaceuticals and patient support systems to have driven recovery.

Zacks Equity Research

DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?

by Zacks Equity Research

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.

Zacks Equity Research

GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?

by Zacks Equity Research

GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.

Zacks Equity Research

Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical Services eyes fourth-quarter growth amid pharma stabilization, biologics rebound & contract manufacturing gains. Can WST sustain its momentum?

Zacks Equity Research

Envista (NVST) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?

by Zacks Equity Research

McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.

Zacks Equity Research

Cencora to Report Q1 Earnings: Is a Beat Likely for the Stock?

by Zacks Equity Research

COR's fiscal first-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Zacks Equity Research

Revvity Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

Zacks Equity Research

Strong Segmental Performance to Drive Stryker's Q4 Earnings?

by Zacks Equity Research

SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits

by Zacks Equity Research

MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.

Zacks Equity Research

Maravai (MRVI) Advances in RNA Research With New Collaboration

by Zacks Equity Research

Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.

Zacks Equity Research

Zynex Inc. (ZYXI) Q3 Earnings Match Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

PetIQ (PETQ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?

by Zacks Equity Research

ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of -9.76% and 4.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?